HDAC9 and lung cancer: In this study, the changes that the combination of the HDAC inhibitor Valproic acid (VPA) and Wnt/β‐Catenin pathway inhibitor Niclosamide (Niclo) may cause in cytotoxicity, apoptosis, cell cycle, and EMT mechanisms in lung cancer cell lines (A549 and H1299) were examined.